Minot DeBlois Advisors’s AstraZeneca AZN Stock Holding History

Minot DeBlois Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.02K	Hold	37	–	–	0.01%	154
2026 Q1	$7.3K	Sell	37 -1	-3%	-$193	0.01%	145
2025 Q4	$6.89K	Hold	38	–	–	0.01%	134
2025 Q3	$5.75K	Hold	38	–	–	0.01%	174
2025 Q2	$5.24K	Hold	38	–	–	0.01%	193
2025 Q1	$5.51K	Hold	38	–	–	0.01%	188
2024 Q4	$4.91K	Buy	+38	New	+$5.32K	﹤0.01%	247

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Minot DeBlois Advisors's AZN Position: Q2 2026 in Review

Minot DeBlois Advisors held its AstraZeneca (AZN) position steady in Q2 2026 at 37 shares worth $7.02K. The position accounts for 0.01% of the portfolio, ranked #154.

Minot DeBlois Advisors first reported a position in AZN in Q4 2024 and has held it in 7 quarters since. The position peaked at $7.3K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Minot DeBlois Advisors held 37 shares of AstraZeneca worth $7.02K as of Q2 2026.
Minot DeBlois Advisors left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.01% of Minot DeBlois Advisors's portfolio in Q2 2026, its #154 holding.
Minot DeBlois Advisors first reported a position in AstraZeneca in Q4 2024 and has held it in 7 quarters since.
Minot DeBlois Advisors's AstraZeneca position peaked at $7.3K in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Minot DeBlois Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.